Shield Therapeutics

Shield is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs.

[Shield Therapeutics @ShieldTx]

We've just released the following announcement: Shield Therapeutics - Total Voting Rights

Check out the full announcement and join in with the conversation at: https://t.co/QGJPRtQ4oQ

#STX

[Shield Therapeutics @ShieldTx]

Today, we mark International Nurses Day, celebrated each year on the birthday of Florence Nightingale to honour the vital contribution nurses make to healthcare worldwide.

#InternationalNursesDay #NursingMatters #Healthcare #NHS #ThankYouNurses

[Shield Therapeutics @ShieldTx]

Shield Therapeutics Q1 2026 Trading Update webinar is now live.

Hear from management on ACCRUFeR® growth and what’s next.

🎥 Watch here:
https://t.co/5DO4sE13uB

[Shield Therapeutics @ShieldTx]

📢 Today at 2:15pm (BST) - our Q1 2026 Trading Update webinar.

CEO Anders Lundstrom, CFO Santosh Shanbhag & CCO Andy Hurley will present, followed by Q&A.

Still time to register 👇

https://t.co/9K3BsMU5TT

[Shield Therapeutics @ShieldTx]

We've just released the following announcement: Shield Therapeutics - Grant of Share Options

Check out the full announcement and join in with the conversation at: https://t.co/S21bQ7xWYD

#STX

[Shield Therapeutics @ShieldTx]

CEO, Anders Lundstrom, CFO, Santosh Shanbhag, and CCO Andy Hurley will be hosting a live webinar relating to the Q1 2026 Trading Update at 2:15 pm (BST) on Tuesday 5 May 2026.
To access the webinar please visit: https://t.co/JiFtWGtKZ8

[Shield Therapeutics @ShieldTx]

Shield Therapeutics plc today releases its unaudited Q1 2026 trading update and announces a CFO transition. For full details visit https://t.co/hzycKix5MJ

[Shield Therapeutics @ShieldTx]

📢 Join us Tuesday 5th May at 2:15pm (BST) for our Q1 2026 Trading Update webinar.

CEO Anders Lundstrom, CFO Santosh Shanbhag & CCO Andy Hurley will present, followed by live Q&A.

Pre-submit questions or ask live on the day.

Register: https://t.co/9K3BsMU5TT

[Shield Therapeutics @ShieldTx]

We've just released the following announcement: Shield Therapeutics - Q1 2026 Trading Update

Check out the full announcement and join in with the conversation at: https://t.co/K3pytQtQ1f

#STX

[Shield Therapeutics @ShieldTx]

We've just released the following announcement: Shield Therapeutics - Total Voting Rights

Check out the full announcement and join in with the conversation at: https://t.co/hLNvTjFzDg

#STX

[Shield Therapeutics @ShieldTx]

Melissa Bryant is the Director of Training at Shield Therapeutics, where she has spent the past two years leading the development and delivery of impactful training programs.
Register | Allego Sales Success Summit 2026

[Shield Therapeutics @ShieldTx]

We've just released the following announcement: Shield Therapeutics - Enrollment in Phase II Clinical Trial for ACCRUFeR

Check out the full announcement and join in with the conversation at: https://t.co/S4unbIR3PT

#STX

[Shield Therapeutics @ShieldTx]

Shield Therapeutics plc announces its audited results for the year ended 31 December 2025. 2025 represents the strongest year on record for ACCRUFeR®, with record prescription volumes, increased average net selling prices, and record revenues. Visit https://t.co/1hyAcowPKS

[Shield Therapeutics @ShieldTx]

We've just released the following announcement: Shield Therapeutics - Audited results for year ended 31 December 2025

Check out the full announcement and join in with the conversation at: https://t.co/qjtlN7rAx7

#STX

[Shield Therapeutics @ShieldTx]

We've just released the following announcement: Shield Therapeutics - Publication of Report, Reinforcing FDA Approval

Check out the full announcement and join in with the conversation at: https://t.co/7Z7YKLCeV3

#STX

[Shield Therapeutics @ShieldTx]

We've just released the following announcement: Shield Therapeutics - EMA approves extension - to include adolescents

Check out the full announcement and join in with the conversation at: https://t.co/vBkr8MO2bl

#STX

[Shield Therapeutics @ShieldTx]

We've just released the following announcement: Shield Therapeutics - Total Voting Rights

Check out the full announcement and join in with the conversation at: https://t.co/9JiFfOsG20

#STX

[Shield Therapeutics @ShieldTx]

David, Andy and Santosh are attending BIO-Europe in Lisbon, Portugal.
We still have a few meeting slots available. If you’re attending and would like to connect via partnering, feel free to reach out.

[Shield Therapeutics @ShieldTx]

David, Andy and Santosh will be attending BIO-Europe in Lisbon, Portugal from 23-25 March 2026.
Our key focus is in-licensing, and we still have a few meeting slots available. If you’re attending and would like to connect via partnering, feel free to reach out.

[Shield Therapeutics @ShieldTx]

We've just released the following announcement: Chinese NMPA Accepts MAA Submission for ACCRUFeR® (ferric maltol)

Check out the full announcement and join in with the conversation at: https://t.co/mabGjwJlay

#STX